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Argonaute2 Regulates the Pancreatic -Cell
Secretome□S
Sudhir G. Tattikota‡, Matthias D. Sury‡, Thomas Rathjen‡, Hans-Hermann Wessels,
Amit K. Pandey, Xintian You, Clinton Becker, Wei Chen, Matthias Selbach§,
and Matthew N. Poy§
Argonaute2 (Ago2) is an established component of the
microRNA-induced silencing complex. Similar to miR-375
loss-of-function studies, inhibition of Ago2 in the pancre-
atic -cell resulted in enhanced insulin release underlin-
ing the relationship between these two genes. Moreover,
as the most abundant microRNA in pancreatic endocrine
cells, miR-375 was also observed to be enriched in Ago2-
associated complexes. Both Ago2 and miR-375 regulate
the pancreatic -cell secretome, and by using quantita-
tive mass spectrometry, we identified the enhanced re-
lease of a set of proteins or secretion “signatures ” in
response to a glucose stimulus using the murine -cell
line MIN6. In addition, the loss of Ago2 resulted in the
increased expression of miR-375 target genes, including
gephyrin and ywhaz. These targets positively contribute
to exocytosis indicating they may mediate the functional
role of both miR-375 and Ago proteins in the pancreatic
-cell by influencing the secretory pathway. This study
specifically addresses the role of Ago2 in the systemic
release of proteins from -cells and highlights the contri-
bution of the microRNA pathway to the function of this cell
type. Molecular & Cellular Proteomics 12: 10.1074/mcp.
M112.024786, 1214–1225, 2013.
The four mammalian Argonaute proteins mediate the
microRNA pathway in mammalian cells by recruiting the non-
coding RNAs to interact with their target mRNAs (1, 2).
Whereas 60% of all mRNAs are predicted to be targets of
microRNAs, the function of individual Argonaute proteins in
this process is largely uncharacterized (3). Interestingly, only
total loss of Argonaute2 (Ago2) expression results in embry-
onic lethality, although genetic deletion of the other family
members does not appear to influence embryonic develop-
ment in the mouse (4). In addition, Ago2 has been shown to
constitute a rate-limiting determinant in RNAi efficacy (5).
Although the role of the Argonaute family has not been eluci-
dated in the pancreatic -cell, miR-375, the most abundant
microRNA in the pancreatic islet, has been shown to regulate
both the growth and function of the -cell (6, 7).
Within the endocrine pancreas, several cell types (, , ,
and pancreatic polypeptide) release hormones into the circu-
lation to regulate a broad spectrum of physiologic pathways
(8). The pancreatic -cell is the only source of insulin in the
body and continuously responds to both glucose and electri-
cal stimuli by releasing proteins into the blood (9). Processing
of the proinsulin molecule occurs during assembly of the
secretory granule when insulin is crystallized leading to the
formation of mature dense-core granules (8). Several reports
suggest the number of proteins in the insulin secretory gran-
ules to range between 50 and 150 as identified using mass
spectrometry (10–12). The dense granules are transported
and stored to comprise a readily releasable pool and, upon
stimulation, fuse to the plasma membrane and constitute
first-phase insulin release (13).
In this study, we address the regulatory role of Ago2 in the
secretion pathway of the pancreatic -cell. Proteins exocyto-
sed from the murine insulinoma cell line MIN6 in response to
glucose into the extracellular environment were quantified
using a stable isotope labeling with amino acids in cell culture
(SILAC)1-based approach (14, 15). Comparison of the pro-
teins detected in the supernatant after induction by high glu-
cose with those inhibited after loss of glucokinase expression
includes a set of secreted -cell proteins or secretion “signa-
ture” This subset includes the most established proteins in the
insulin secretory granule as follows: insulin1 and -2; carboxy-
peptidase E, and the family of chromogranin and secretogra-
nin proteins (8, 16). Moreover, siRNA-mediated knockdown of
Ago2 resulted in increased secretion of this set of proteins in
response to glucose, suggesting a prominent role for this
gene and the microRNA pathway in regulating the -cell
secretome. In addition, immunoprecipitation of Ago2
showed enriched isolation of miR-375 indicating this spe-
cific member of the Argonaute family is essential for recruit-
ing this microRNA to its target genes.
Taken together, this study establishes through the use of a
pancreatic -cell model the signature set of proteins releasedFrom the Max Delbrueck Center for Molecular Medicine, Robert
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in response to glucose. In addition to the major constituents
present in the insulin granule, the diversity in the identified
proteins suggests the -cell is a source of signaling factors
that potentially influence a wide range of physiologic pro-
cesses. Furthermore, we identify Ago2 as a primary mediator
of miR-375 function indicating together these two genes play
a major role in directing the secretory machinery in -cells and
in facilitating glucose homeostasis and metabolism.
EXPERIMENTAL PROCEDURES
Cell Culture, Subcellular Fractionation, Ribonucleoprotein Immuno-
precipitation, and Antibodies—MIN6 cells were cultured in DMEM
(Invitrogen) containing 4.5 g/liter glucose supplemented with 15% v/v
heat-inactivated FCS, 50 M -mercaptoethanol, 50 mg/ml penicillin,
and 100 mg/ml streptomycin. Insulin release was performed as de-
scribed previously (7). Ribonucleoprotein immunoprecipitation exper-
iments using Ago1 and Ago2 antibodies were performed as described
previously (1, 17). For subcellular fractionation, cells were scraped
into PBS, pelleted (300  g, 5 min at 4 °C), and resuspended (0.3 M
sucrose, 4 mM HEPES, pH 7.4, 0.5 mM EGTA). The homogenate was
spun (3,000  g, 10 min at 4 °C), and the postnuclear supernatant
was loaded onto an eight-step sucrose gradient (HEPES buffered 0.2
to 2.0 M sucrose) and spun (55,000  g, 2 h at 4 °C) using an MLS50
rotor (Beckman Coulter) as described previously (18). Antibodies for
immunoprecipitation and Western blotting were used as follows:
Gephyrin (BD Biosciences 610584); Ywhaz (Abcam ab61129); Rasd1
(Millipore AB15794); Grp78 (Assay Designs StressGen SPA-826); N-
ethylmaleimide-sensitive factor (BD Biosciences 612272); Rab3A (Ab-
cam ab3335); Ago2 (for immunoprecipitation) (Wako 018-22021);
Ago2 (for Western blotting) (C34C6); Ago1 (MBL RN028PW); Dicer
(Bethyl A301-936A); HuD/Elavl4 (Santa Cruz Biotechnology sc-
48421); -tubulin (Sigma-Aldrich T6557), and -actin (Sigma-Aldrich
A2066).
Animals—Mice were maintained in a 12-h light/dark cycle with ad
libitum access to regular chow in accordance to Landesamt fu¨r Ge-
sundheit und Soziales (Lageso). All experimental procedures were
approved under protocols G 0357/10, O 0405/09, and T 0436/08.
Small RNA Deep Sequencing—Small RNA sequencing libraries
were prepared using Illumina small RNA library preparation kits. Small
RNA fractions with a size range of 10–40 nucleotides were separated
using FlashPAGE Fractionator (Ambion) according to the manufac-
turer’s instructions. The small RNA fractions were ligated sequentially
at the 3 and 5 ends with synthetic RNA adapters, reverse-tran-
scribed, and amplified using Illumina sequencing primers. Amplified
libraries were purified by PAGE according to the expected product
size. Libraries were sequenced for 50 cycles (Illumina Hi-seq 2000),
and the 3 adapter sequences were removed using a custom Perl
script. Reads of a length between 17 and 30 nucleotides were re-
tained and mapped to known mouse pre-microRNA sequences de-
posited in the miRBase (19) without allowing any mismatch using
soap1 and soap.short (20), respectively.
Gene Expression Analysis—All siRNAs and cholesterol-conjugated
microRNA inhibitors (Riboxx GmbH (Radebeul, Germany)) were trans-
fected into MIN6 cells with the Amaxa electroporation kit V (Lonza)
and Lipofectamine 2000 (Invitrogen), respectively. Gene expression
studies were analyzed 48 h after transfection, and total RNA was
isolated with TRIzol, and cDNA was reverse-transcribed using a
RevertAid First Strand cDNA synthesis kit (Fermentas). Quantitative
real time PCR (qPCR) for small RNAs was performed using ABI
microRNA assays and was normalized to U6 snRNA expression
(Applied Biosystems) as described previously (21). Relative quan-
tification by RT-PCR of Argonaute genes was determined from
cDNA derived from MIN6 cells using gene-specific primers. Nor-
malization was calculated with standard curves established with
Ago1–4 cDNA constructs. Gene-specific primers were used with
FastStart SYBR Green PCR Master Mix (Roche Applied Science)
and are available upon request.
SILAC Labeling and Transfections—For SILAC labeling, MIN6 cells
were grown in high glucose DMEM (PAA Laboratories GmbH, Pas-
ching, Austria) supplemented with 15% dialyzed FCS (Sigma-Aldrich),
4 mM glutamine (PAA Laboratories GmbH, Pasching, Austria), 100
units/ml penicillin, 50 M -mercaptoethanol, 100 g/ml streptomycin
(Invitrogen), 48 g/ml Lys-C6H14N2O2 (Lys-0) and 28 g/ml Arg-
C6H14N4O2 (Arg-0) (Sigma-Aldrich), or 48 g/ml Lys-
13C6 H14
15N2O2
(Lys-8) and 28 g/ml Arg-13C6H14
15N4O2 (Arg-10) (Sigma Isotec).
Eight passages in “heavy DMEM ” were conducted to achieve a high
degree of incorporation of the heavy isotopes into proteins (95.12 
4.3% labeling efficiency). For secretion experiments, SILAC-labeled
MIN6 cells were washed six times before incubating for 1 h in mod-
ified Krebs-Ringer buffer containing either low (2.8 mM) or high (25
mM) glucose, as described previously (7). Supernatants of light and
heavy MIN6 cell cultures were combined and concentrated with Ami-
con Ultra-15 centrifugal filter units with a 3-kDa cutoff (EMD Millipore
Corp.). Proteins were precipitated and dissolved in 6 M urea, 2 M
thiourea. Proteins were reduced and alkylated. Lysyl endopeptidase
(LysC) (Wako, Osaka, Japan) and trypsin (Promega, Madison, WI)
were used for in-solution digestion. Stop and go extraction (STAGE)
tips containing C18 empore disks (3M, Minneapolis, MN) were used to
purify and store peptide extracts (22).
LC-MS/MS—LC-MS/MS analysis was performed as described
previously (23). Briefly, peptide mixtures were separated by reversed
phase chromatography using the EASY-nLC system (Thermo Fisher,
Waltham, MA) on in-house manufactured 20-cm fritless silica micro-
columns with an inner diameter of 75 m. Columns were packed with
ReproSil-Pur C18-AQ 3-m resin (Dr. Maisch GmbH, Ammerbuch,
Germany). Peptides were separated on a 8–60% acetonitrile gradient
(182 min) with 0.5% formic acid at a flow rate of 200 nl/min. Eluting
peptides were directly ionized by electrospray ionization and trans-
ferred into an LTQ-Orbitrap-Velos or Q-Exactive mass spectrometer
(Thermo Fisher, Waltham, MA). Q-Exactive measurements were per-
formed using a “sensitive” acquisition method as described previ-
ously (24). In short, one full scan (m/z  300–1,700; R  70,000;
target value  3  106; maximum injection time  120 ms) was
followed by 10 MS/MS scans (charge 1; R  35,000; target value 
5  105; isolation window  4 m/z; maximum injection time  120
ms). Dynamic exclusion for selected precursor ions was 30 s.
Processing of MS Data—MaxQuant software package (version
1.2.2.5) with default settings was used to identify and quantify
proteins (25). In brief, SILAC duplets were quantified using the
following settings: heavy label Lys-8, Arg-10; maximum of three
labeled amino acids per peptide; top 10 MS/MS peaks per 100 Da.
Carbamidomethylation of cysteine was selected as fixed modifica-
tion; oxidation of methionine and acetylation of the protein N ter-
minus were used as variable modifications. Trypsin was selected as
protease (full specificity) with a maximum of two missed cleavages.
Mass tolerance of precursor ions was set to 6 ppm and for fragment
ions to 20 ppm. MS/MS spectra were searched using the Androm-
eda search engine against an IPI mouse database (release 3.84),
which totaled 60,012 proteins in addition to 248 common contam-
inants (26). All protein sequences were also reversed to generate a
target-decoy database. A minimum of six amino acids per identified
peptide and at least one peptide per protein group was required.
False discovery rate was set to 1% at both the peptide and protein
levels. Protein ratios were calculated from the median of all nor-
malized peptide ratios using only unique peptides or peptides
assigned to the protein group with the highest number of peptides
(razor peptides). Only protein groups with at least three SILAC
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counts were considered for further analysis. The data associated
with this study may be downloaded from the ProteomeCommons.
org Tranche network using the following hash: http://cptac.
tranche.proteomecommons.org/.
Bgen4cngG5NvlPcKObF59By9BhSkmp7fwYLA1r1KKhvejSDn5Ba
oeDoXMgLUNxACDXNJdy.
Bgen4cngG5NvlPcKObF59By9BhSkmp7fwYLA1r1KKhvejSDn5Ba
oeDoRGnG5M5wHfu9wZr.
Bgen4cngG5NvlPcKObF59By9BhSkmp7fwYLA1r1KKhvejSDn5Ba
oeDoYh9YAAAAAAAAKlQ.
Bgen4cngG5NvlPcKObF59By9BhSkmp7fwYLA1r1KKhvejSDn5Ba
oeDorudnicketal.html.
Statistical Analysis—All results are expressed as means  S.E.
Comparisons between data sets with two groups were evaluated
using an unpaired Student’s t test. Analysis of variance was per-
formed for comparisons of three or more groups. A p value of less
than or equal to 0.05 was considered statistically significant. Cluster
analysis of gene ontology (GO) terms was performed using the DAVID
Bioinformatics Database (DAVID Bioinformatics Resources, National
Institutes of Health, NCI-Frederick, MD).
RESULTS
Argonaute2 Regulates Insulin Release from the Pancreatic
-Cell—To date, the functional role of the Argonaute proteins
in the pancreatic -cell has not been described. qPCR for the
four identified members of the Argonaute family showed Ago2
to be the most abundant as described in other tissues (Fig.
1A) (1). Moreover, siRNA-mediated knockdown of Ago2 in
MIN6 cells resulted in a mild but significant 1.2–1.4-fold in-
crease of Ago1, Ago3, and Ago4 mRNA levels (Fig. 1B). In
contrast, knockdown of Ago1 had no effect on the expression
of other family members (Fig. 1C). Similar to previous loss of
function studies of miR-375 in MIN6 cells, siRNA-mediated
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FIG. 1. Argonaute2 associates withmiR-375 to regulate pancreatic -cell secretion. A, relative quantification of Ago genes by qRT-PCR.
B and C, qRT-PCR analysis of Ago genes after siRNA-mediated knockdown of Ago2 and Ago1 in MIN6 cells (n  3). D, measurement of
glucose-stimulated insulin release in MIN6 cells after both siRNA-mediated knockdown of Ago2 and inhibition of miR-375 compared with
scrambled controls (n  3). E, comparison of small RNA deep sequencing analysis of total RNA isolated from the MIN6 cell line and isolated
pancreatic islets of 10-week-old C57BL/6 mice. F, qRT-PCR analysis of miR-375 after siRNA-mediated knockdown of Ago1 and Ago2 in MIN6
cells (n  3). G, detection of Argonaute proteins after immunoprecipitation (IP) with -Ago1 and -Ago2 antibodies and quantification of
miR-375 by qRT-PCR after isolation of total RNA from Ago1- and Ago2-associated complexes. Ctrl, control. Results are presented as mean 
S.E. *, p  0.05; **, p  0.01; and ***, p  0.001. AU is arbitrary units.
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knockdown of Ago2 in MIN6 cells resulted in increased glu-
cose-stimulated insulin release (Fig. 1D and supplemental Fig.
1A) (7). The effects on insulin secretion after inhibition of either
Ago2 or miR-375 are very comparable and may be either a
reflection of the predominant expression of these genes in this
cell type or indicative of a functional association between
these two molecules. Small RNA sequencing profiles of both
MIN6 cells and pancreatic islets isolated from 10-week-old
wild-type C57BL/6 mice showed that miR-375 is the mi-
croRNA with the highest read counts in both tissues (Fig. 1E
and supplemental Table 1). Interestingly, loss of Ago1 and
Ago2 expression incurred a decrease in miR-375 levels sup-
porting previous results that the stability of microRNAs is
dependent on Argonaute proteins (Fig. 1F) (1).
To determine the relative association of miR-375 with Ago1
and Ago2, qRT-PCR was performed after immunoprecipita-
tion of the Ago1 and Ago2 proteins as described previously
(1). Although Ago1 and Ago2 were detectable following pull-
down compared with IgG control, an increased amount of
Ago1 was observed following knockdown of Ago2 (Fig. 1G).
Moreover, immunoprecipitation of Ago2 revealed an enriched
level of miR-375 compared with the pulldowns of Ago1. These
results show an increased abundance of miR-375 to be as-
sociated with Ago2 and not Ago1 and support the similarity in
the effects on insulin secretion after inhibition of either miR-
375 or Ago2.
Quantitative Analysis of the Pancreatic -Cell Secre-
tome—To evaluate the regulatory role of Ago2 in the secretory
pathway, we used the MIN6 cell line as a glucose-responsive
model system for the study of -cell function (27). To accu-
rately quantify proteins released in response to glucose, we
employed a SILAC-based strategy (Fig. 2A). Light SILAC-
labeled MIN6 cells were incubated with low glucose (2.8 mM,
low Glc), whereas heavy cells were treated with high glucose
(25 mM, high Glc). Supernatants from differentially labeled
samples were combined, concentrated, digested, and ana-
lyzed by high resolution shotgun proteomics. As an additional
control, experiments were also performed with swapped
SILAC labels (a reversed experiment). As expected, log2 fold
changes of proteins quantified in both experiments show a
strong anti-correlation (Fig. 2B). On average, 500 proteins
were quantified in the supernatants of both experiments.
However, only a small subset of these proteins was detected
to robustly change in response to glucose, i.e. it had a high
ratio in the forward and a low ratio in the reverse experiment
(log2 fold change 0.5 and log2 fold change less than 0.5,
respectively). To validate if these changes in the secretome
are specifically induced by the response of cells to glucose,
we used siRNAs to knock down the glucose sensor glucoki-
nase (si-Gck) (Fig. 2C). Of the proteins that were found to be
secreted in the high/low glucose experiments, 48 proteins
were also identified to be regulated by glucokinase (log2 fold
change less than 0.5) validating that the observed changes
in the -cell secretome are glucose-dependent (Table I and
Fig. 2, C and D). An analysis of these 48 robustly quantified
proteins in the -cell secretome revealed specific enrichment
for specific categories of Gene Ontology (GO) cellular com-
partments, including secretory granule (p  3.77E-8), cyto-
plasmic membrane-bounded vesicle (p  4.23E-5), and ex-
tracellular region (p  1.18E-14), including both insulin
paralogs in mouse (Ins1 and Ins2). These 48 proteins consti-
tuted the basis of the secretome signature in subsequent
analyses. Proteins quantified in only two of the three secre-
tome samples were included as an additional resource of
potential components of the MIN6 secretome (Table II).
Ago2 Is a Regulator of the Pancreatic -Cell Secre-
tome—To address the regulatory role of Ago2, we analyzed
glucose-induced secretion after siRNA-mediated knockdown
of Ago2 in MIN6 cells using the same proteomic approach.
We observed that inhibition of Ago2 (si-Ago2) resulted in a
significant enhancement of secretion of dozens of proteins
compared with a scrambled control (si-Ctrl) (Fig. 3A). Impor-
tantly, knockdown of Ago2 induced hypersecretion of the
same proteins that were also secreted in response to high
glucose (Fig. 3B). Hence, Ago2 may function as a master
regulator of the glucose-induced -cell secretome. Next, to
test if Ago2 regulates secretion via miR-375, we analyzed the
glucose-induced secretome after inhibition of this microRNA
by transfecting cholesterol-conjugated 2-O-methylated anti-
sense oligonucleotides (Cnt-375) compared with control oli-
gonucleotides (Cnt-Ctrl) (Fig. 3C and supplemental Fig. 1, A
and B). Although the variability was greater than in the Ago2
knockdown experiment, we also found that miR-375 inhibition
reproducibly induced hypersecretion of dozens of proteins.
Importantly, we observed a strong correlation of changes in
the secretome after both Ago2 and miR-375 inhibition, high-
lighting the functional overlap between these molecules with
respect to regulating secretion in these cells (Fig. 3D).
Argonaute2 Mediates the Effect of miR-375 on Target Gene
Expression—To validate whether Ago2 indeed mediates the
effect of miR-375 in pancreatic -cells, we next measured
expression of validated miR-375 targets after inhibition of
Ago2 by qRT-PCR. Several validated targets of miR-375,
including Elavl4/HuD, Gphn, and Rasd1, were all measured to
be up-regulated after Ago2 knockdown indicating that steady
state mRNA levels of these genes are dependent on this
specific member of the Argonaute family (Fig. 4A) (6). Both
Pictar and TargetScan algorithms identified a conserved seed
sequence of miR-375 in the 3UTR of Ywhaz, and real time
PCR showed an increase in expression after inhibition of the
microRNA (Fig. 4B) (28, 29). Regulation of Elavl4/HuD, Gephy-
rin, Ywhaz, and Rasd1 was also confirmed by Western blot-
ting after both knockdown (si-Ago2) and overexpression
(Ago2OE) of Ago2 (Fig. 4, C and D). Moreover, expression of
Gephyrin and Ywhaz was unchanged after knockdown of
Ago1, indicating this member of the Argonaute family plays a
lesser role in mediating regulation of these targets by miR-375
(Fig. 4E). However, Rasd1 was observed increased after
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knockdown of both Ago1 and Ago2 by Western blotting indi-
cating its regulation by miR-375 may be mediated by multiple
Argonaute proteins (Fig. 4E). Finally, we observed that inhibi-
tion of Ago1 resulted in a decrease of Elavl4/HuD expression
suggesting perhaps other Ago family members mediate its
regulation in the absence of Ago1. These results show that the
targeting of many genes by miR-375 is more dependent upon
Ago2 than other Ago proteins and can explain the functional
overlap in regulating insulin secretion.
Target Genes of miR-375 Contribute to Insulin Release from
the Pancreatic -Cell—To determine which of the identified
targets of miR-375 contribute to its role in secretion, we
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FIG. 2. Establishment of glucose-induced secretome analysis in MIN6 cells. A, workflow for labeling of MIN6 cells with heavy
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13C6H14
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difference (8 Da for lysine-containing peptides and 10 Da for arginine-containing peptides). Consistently, the ratio of peak intensities of H versus
L peptides reflects differences in protein abundance. B, supernatants of heavy labeled cells treated with 25 mM glucose and of light labeled
cells treated with 2.8 mM glucose were combined and analyzed by LC-MS/MS. In addition, a label swap experiment was performed. In total,
498 proteins were quantified. Regulated signature proteins are colored in red (log2 fold change 0.5 and log2 fold change less than 0.5, n 
48). Among these proteins, insulin-1 and insulin-2 were identified. C, LC-MS/MS analysis of mixed supernatants of glucokinase (Gck) siRNA
knockdown (heavy) and siRNA control cells (light) after 25 mM glucose treatment. In total, 796 proteins were quantified. Regulated proteins
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glucose/low glucose experiments and from the glucokinase knockdown experiment. Gene ontology (GO) analysis of cellular compartments
was performed on the 48 proteins ( secretome signature) shared in all three experiments using DAVID. Benjamini Hochberg corrected p
values are shown. All proteins from the Venn diagram are listed in Table I.
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TABLE I
List of “secretion signature” factors in response to 25 mM glucose incubation of MIN6 cells
Protein names Uniprot Gene names
Ratio normalized
high glucose/low
glucose
Ratio normalized
low glucose/high
glucose
Ratio normalized
after si-Gck/
si-ctrl
No. of
peptides
C-flanking peptide of NPY P57774 Npy 4.52 2.10 1.26 5
Insulin-1 P01325 Ins1 4.27 1.29 1.45 5
IGF-II E9QLW5 Igf2 4.18 2.75 1.47 7
Carboxypeptidase E Q00493 Cpe 4.07 2.35 1.18 43
Chromogranin-B P16014 Chgb 3.99 2.18 1.32 54
Preprodynorphin O35852 mCG_9904 3.98 2.51 1.20 14
Chromogranin-C Q03517 Chgc 3.98 2.28 1.31 53
VGF nerve growth factor inducible Q0VGU4 mCG_18019 3.96 2.46 1.30 39
Neuronal pentraxin receptor Q3UH37 Nptxr 3.95 1.96 1.23 17
Protein-tyrosine phosphatase,
receptor type, N polypeptide 2
A3KN68 Ptprn2 3.90 2.55 1.13 31
Furin homolog P63239 Att-1 3.84 2.20 1.20 38
Secretogranin III P47867 Scg3 3.82 2.46 1.12 44
KEX2-like endoprotease 2 P21661 Nec2 3.78 2.08 1.05 31
C-terminal peptide P12961 Scg5 3.77 2.18 1.19 10
Neuronal pentraxin I Q62443 Nptx1 3.73 1.99 0.76 18
Receptor-type tyrosine-protein
phosphatase-like N
E9Q746 Ptprn 3.70 2.44 1.22 16
Ribonuclease 4 Q5UCA9 Rnase4 3.63 1.85 1.48 7
DnaJ (Hsp40) homolog, subfamily B,
member 9
Q5D0C3 Dnajb9 3.63 1.88 1.33 10
Protein OS-9 Q8K2C7–1 Os9 3.51 1.77 1.44 17
Big LEN Q9QXV0 Pcsk1n 3.51 3.01 1.07 13
Lysyl oxidase homolog 2 P58022-1 Loxl2 3.31 1.99 1.12 29
Peptidyl--hydroxyglycine -amidating
lyase
E9QL07 Pam 3.31 2.37 1.31 35
Neuronal pentraxin II O70340 Nptx2 3.26 1.73 0.84 19
Spock1 protein B2RXY1 Spock1 3.22 2.25 1.43 11
Angiogenin P21570 Ang 3.11 1.80 1.19 7
Cystatin-3 P21460 Cst3 3.09 1.16 1.19 8
Insulin-2 P01326 Ins2 2.97 1.12 1.27 7
Bone morphogenetic protein 1 Q6NZM2 Bmp1 2.94 2.64 1.40 13
SPARC/osteonectin, CWCV, and
Kazal-like domains proteoglycan 2
Q9ER58 Spock2 2.85 0.52 0.85 11
Brain-specific receptor-like protein A Q4V9Z5–2 Sez6l2 2.79 0.70 1.29 25
Glicentin P55095 Gcg 2.69 1.60 1.12 14
Vitamin D-binding protein P21614 Gc 2.59 1.33 1.46 18
E-selectin ligand 1 Q61543 Esl1 2.54 0.75 1.06 41
Golgi membrane protein 1 Q91XA2 Golm1 2.38 1.45 1.83 7
Putative uncharacterized protein
Golim4
D3YVW2 Golim4 2.35 0.97 1.79 12
Pappa2 protein E9PZ87 Pappa2 2.30 1.66 1.27 50
Prosaposin Q3UE29 Psap 2.30 1.68 0.61 18
45-kDa calcium-binding protein Q61112–1 Cab45 2.16 0.78 1.16 22
Ribosomal protein L1 Q3U561 Rpl10a 1.83 1.48 0.61 13
Fetuin-B Q9QXC1 Fetub 1.77 2.13 0.84 14
Chondroitin sulfatase Q571E4 Galns 1.47 0.68 0.96 24
Acid ceramidase Q9WV54 Asah 1.15 0.52 0.82 17
ABPP P12023–1 App 1.01 0.77 0.85 22
Fam3c protein Q6NSU0 D6Wsu176e 0.91 1.13 0.93 9
-N-Acetylglucosaminidase (Sanfilippo
disease IIIB)
A2BFA6 Naglu 0.88 1.02 1.11 21
Amylin P12968 Iapp 0.81 2.25 1.92 4
-Glutamyl hydrolase B1AWC1 Ggh 0.71 0.86 0.81 11
-Hexosaminidase subunit  P20060 Hexb 0.53 0.55 0.74 22
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utilized siRNA-mediated knockdown in MIN6 cells to test their
effect on insulin release. Previous studies by our group have
shown that seven genes are targets of miR-375, including
Myotrophin, Gephyrin, HuD/Elavl4, Aifm1, Rasd1, Eef1e1, and
Cadm1 (6, 7). Inhibition of Gephyrin, Ywhaz, Aifm1, and Mtpn
all resulted in lower insulin levels in response to 25 mM glu-
cose compared with transfected control cells (Fig. 5A and
supplemental Fig. 2, A and B). These results would suggest
that these four genes play an important role because loss of
either Ago2 and miR-375 expression resulted in enhanced
secretion.
In addition, in light of the robust regulation of Gephyrin and
Ywhaz after knockdown of Ago2, we then addressed whether
these proteins may localize with proteins present in insulin
secretory granules. We performed subcellular fractionation
using a sucrose gradient with MIN6 cell extracts to under-
stand which compartments within the -cell these proteins
occupy. Immunoblotting for Gephyrin and Ywhaz showed
these proteins are all present in regions distinct from insulin
secretory granule-containing fractions as identified by radio-
immunoassay (Fig. 5B). Moreover, the fractions enriched for
these granules overlapped with peaks in expression for
Rab3A and N-ethylmaleimide-sensitive factor and was in con-
trasting comparison with the endoplasmic reticulum marker
Grp78 (Fig. 5B). In light of these results, we therefore inves-
tigated if miR-375-mediated repression of gephyrin might
control the -cell secretome. To this end, we quantified the
impact of gephyrin knockdown on the glucose-stimulated
secretome (Fig. 5C). We observed that loss of Gephyrin re-
duced secretion of dozens of proteins (including the secre-
tome signature) that are hypersecreted after inhibition of miR-
375. Thus, Gephyrin and miR-375 have opposing effects on
glucose-mediated secretion and reinforce the notion that
gephyrin is a functional target of this microRNA. Finally, se-
cretome profiles after high glucose treatment (Fig. 2B) or loss
of miR-375 expression (supplemental Fig. 1B) did not show
enrichment of miR-375 seed-containing genes among the
proteins identified (supplemental Fig. 1, D and E, respec-
tively). Therefore, instead of targeting individual secreted pro-
teins, miR-375 appears to globally regulate secretion from the
-cell. Specifically, miR-375 may target genes that have a
regulatory function for glucose-stimulated secretion.
DISCUSSION
The precise release of insulin from the pancreatic -cell
requires the coordinated effort of numerous pathways to
maintain physiologic levels of glucose in the blood (30, 31).
MicroRNAs have been shown to contribute a significant reg-
ulatory role to the growth and function of the pancreatic
-cell, the sole source of insulin and many other factors to the
systemic circulation (32). Central to microRNA function is the
Argonaute family of proteins; however, the extent to which
individual members contribute to the activity of specific mi-
croRNA is largely uncharacterized (2). miR-375, the highest
expressed microRNA in both MIN6 cells and pancreatic islets,
has been previously shown to regulate exocytosis from
TABLE II
List of factors that were detected in two experiments in response to 25 mM glucose incubation of MIN6 cells
Protein names Uniprot Gene names
Ratio normalized
high glucose/low
glucose
Ratio normalized
low glucose/high
glucose
Ratio normalized
after si-Gck/
si-ctrl
No. of
peptides
C-reactive protein E9PZ20 Crp 3.31 0.72 9
Transthyretin P07309 Ttr 2.42 0.98 13
Ptprz1 protein B2RXS8 Ptprz1 2.26 1.49 16
Cathepsin L1 P06797 Ctsl 2.15 1.09 7
4632419I22Rik protein Q6NXM5 4632419I22Rik 2.15 1.08 9
Protein C7-1 Q9R1Q9 Atp6ap1 2.09 0.99 6
HEPACAM family member 2 Q4VAH7 Hepacam2 2.01 1.15 7
CALNUC Q02819 Nuc 1.61 0.93 37
Cathepsin Z Q9WUU7 Ctsz 1.48 0.61 13
Palmitoyl-protein hydrolase 1 O88531 Ppt 1.41 0.72 11
Cyp-C-associated protein Q07797 Cycap 1.32 -0.84 16
Neuronal cell adhesion molecule Q810U4–3 Kiaa0343 1.31 1.83 37
-Hexosaminidase subunit  P29416 Hexa 1.16 0.82 22
Cathepsin A Q9D2D1 Ctsa 1.07 0.72 20
Hematopoietic lineage switch 2 Q9WVJ3–1 Hls2 0.78 0.58 14
Neural cell adhesion molecule 1 P13595–1 Ncam 0.73 1.10 19
Mannosidase 2, B1 Q3TB95 Man2b1 0.66 0.56 31
Hypoxia up-regulated protein 1 Q9JKR6 Grp170 0.55 0.95 44
Ectonucleotide pyrophosphatase/
phosphodiesterase family
member 5
Q9EQG7 Enpp5 1.19 0.64 15
Insulin-like growth factor 2
receptor
Q07113 Igf2r 0.78 1.14 21
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-cells as well as growth of the endocrine pancreas (6, 7). In
this study, we show that loss of Ago2 expression in the -cell
also results in increased release of insulin underlining an
important functional role for the microRNA pathway in this cell
type.
As miR-375 constitutes the largest percentage of the total
pool of microRNAs in pancreatic islet cells, this observation
may explain several similarities between loss of Ago2 and
miR-375 models. As observed in other tissues, Ago2 was
measured to be the most abundant of all Ago family members
in MIN6 cells, and immunodepletion of Ago2 precipitated
higher levels of miR-375 (1, 33). Together these molecules
may constitute a large proportion of microRNA-induced si-
lencing complexes, and therefore the effects on insulin re-
lease are similar in magnitude.
Additionally, inhibition of miR-7, a microRNA shown to in-
fluence endocrine differentiation, results in enhanced secre-
tion of the signature proteins indicating several microRNAs
may contribute to this process in the -cell (supplemental Fig.
3, A–C) (34). However, loss of Dicer expression resulted in
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FIG. 3. Argonaute2 regulates the pancreatic -cell secretome. A, comparison of quantitative analysis of proteins present in supernatant
of MIN6 cells after incubation in 25 mM glucose. One experiment quantified proteins after siRNA-mediated knockdown of Ago2 in MIN6 (labeled
in heavy SILAC media) compared with control (labeled in light SILAC media). A converse experiment was performed with knockdown of Ago2
using light labeled cells (label swap experiment). B, comparison of quantitative analysis of proteins present in supernatant after siRNA-
mediated knockdown of Ago2 in MIN6 cells after incubation in 25 mM glucose with an experiment measuring proteins present in the
supernatant of MIN6 cells after incubation in 25 mM glucose (Hi Glc) versus 2.8 mM glucose (Lo Glc). C, secretome experiment exhibiting
comparison of quantitative analysis of proteins present in supernatant of MIN6 cells after inhibition of miR-375 and incubation in 25 mM glucose
(labeled in heavy SILAC media) and the corresponding label swap experiment. D, comparison of quantitative analysis of proteins present in
supernatant of MIN6 cells after inhibition of miR-375 and incubation in 25 mM glucose versus experiment after siRNA-mediated knockdown
of Ago2. Proteins colored in red are defined as the secretome signature.
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decreased insulin release, but this effect disappeared after
normalization with decreased cellular insulin content consist-
ent with previous studies showing Dicer maintained insulin
mRNA expression (supplemental Fig. 4, A–C and supplemen-
tal Table 2) (35). Furthermore, although Dicer knockdown
decreased the overall microRNA expression profile, it is hy-
pothesized to perform several functions in addition to its role
in microRNA processing such as the maintenance of hetero-
chromatin structure (36). Therefore, it is unclear whether these
results are due directly to the loss of Dicer itself or to the
overall microRNA expression. Together, these observations
show that several microRNAs may regulate the secretory
pathway. However, loss of Dicer and overall microRNA ex-
pression negatively impacts secretion by decreasing insulin
mRNA expression due to essential functions of these genes
inherent to this cell type.
Our results showing miR-375 target genes to be up-regu-
lated after inhibition of Ago2 further underlines the functional
association between these two genes. The absence of any
effect after loss of Ago1 on insulin release may reflect an
important functional difference in the role of miR-375 and
Ago2 in the pancreatic -cell. Although miR-375 does asso-
ciate with Ago1, these results may simply reflect the relative
abundance of Ago1 and the amount of miR-375 present in
Ago1-associated complexes. In addition, the identification of
gephyrin and ywhaz as both regulators of insulin release and
likely direct targets of miR-375 brings to light a functional
association between these specific genes. Although both oc-
cupy compartments independent of insulin secretory gran-
ules, previous studies on Gephyrin have described its asso-
ciation with glycine receptors within the secretion pathway of
post-synaptic compartments, and it is hypothesized to con-
tribute to the dynamics of protein localization within synaptic
assemblies (37). Moreover, Gephyrin was shown to facilitate
the transport of glycine receptors along the microtubules en
route to the plasma membrane (38). Meanwhile, Ywhaz (14-
3-3) was shown to interact with Limk1 and cofilin to regulate
actin dynamics, a process contributing to exocytosis (39). Of
note, recent studies on Elavl4/HuD describe its role in regu-
lating translation of the insulin mRNA, and transgenic overex-
pression in mice resulted in impaired insulin release (40).
Furthermore, inhibition of Rasd1 was shown to result in in-
creased insulin release in MIN6 cells (41). Taken together,
these results indicate targets of miR-375 can either positively
0.82 γ-tubulin
1.87 * Rasd1
1.71 *
1.56 * 
si-Ctrl              si-Ago2        fold ch.
Ago2
HuD/Elavl4
0.21 **
3.65 **Ago1
Gephyrin
1.99 *
Ywhaz
D
Rasd1 0.69 * 
Ago2
HuD/Elavl4
2.34 *
0.51 *Ago1
Gephyrin 0.55 *
Ywhaz 0.84  
1.03γ-tubulin
Ctrl OE           Ago2OE        fold ch.
0.33 *
E
A B
0.0
0.5
1.0
1.5
Ywhaz
Cnt-Ctrl
Cnt-375
re
l. 
ex
pr
es
si
on
 (A
U
) *
C
Ago1
HuD/Elavl4
0.42 ***
1.25 Ago2
Gephyrin 1.21
Ywhaz 1.11
1.05γ-tubulin
si-Ctrl              si-Ago1         fold ch.
0.46 *
Rasd1 2.01 *
si-control
si-Ago1
si-Ago2
0.0
0.5
1.0
1.5
2.0
Elavl4    Gphn Ywhaz   Rasd1
** **
re
l. 
ex
pr
es
si
on
(A
U
)
*
2.5
**
re
l. 
ex
pr
es
si
on
(A
U
)
FIG. 4. Loss of Argonaute2 increases expression of miR-375 targets. Argonaute2 and miR-375 cooperate in the regulation of -cell
secretion. A, qRT-PCR analysis of miR-375 target genes after siRNA-mediated knockdown of Ago1 and Ago2 in MIN6 cells (n  4). B,
qRT-PCR analysis of Ywhaz after inhibition of miR-375 in MIN6 cells (n 4). C,Western blotting analysis of Ago2, Ago1, Elavl4/HuD, Gephyrin,
Ywhaz, and Rasd1 after siRNA-mediated knockdown of Ago2 compared with scrambled control. D, Western blotting analysis of Ago2, Ago1,
Elavl4/HuD, Gephyrin, Ywhaz, and Rasd1 after overexpression of Ago2 (Ago2OE) compared with transfection control. E, Western blotting
analysis of Ago1, Ago2, Elavl4/HuD, Gephyrin, Ywhaz, and Rasd1 after siRNA-mediated knockdown of Ago1 compared with scrambled
control. fold ch, fold change. Results are presented as mean  S.E. *, p  0.05; **, p  0.01; and ***, p  0.001. AU is arbitrary units.
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or negatively influence secretion, and therefore only after the
identification of all targets can we reach an understanding of
the complexity of its role in the -cell.
Our observations showing overall enhanced secretion in
response to glucose after inhibiting either Ago2 or miR-375
may suggest the microRNA pathway functions to prevent the
excessive release of proteins into the blood. We showed an
enhancement of insulin release after loss of Ago2 expression,
and alterations in the expression of actin and microtubule-
associated proteins Gephyrin and Ywhaz may suggest a role
for the microRNA pathway in maintaining the precise timing of
recruitment, docking, or fusion of the insulin secretory gran-
ules. As insulin release is modulated according to changes in
stimuli, microRNAs may function as a strict regulatory mech-
anism over excessive insulin release to ensure normal glucose
homeostasis.
Importantly, many of the proteins identified within the pro-
teomic analysis are known components of the insulin granule
and constitute the basis for the secretome signature. As ex-
pected, Insulin1 and -2, the products of the two insulin genes
present in both mouse and rat, were detected in the super-
natants in response to glucose (42). In addition, it was also
expected that the majority of proteins in the chromogranin
and secretogranin family would be identified (12, 43). Inter-
estingly, VGF was also detected and was recently described
to promote pancreatic -cell survival and function during the
onset of diabetes (44). Therefore, the identification of the
pancreatic -cell secretome presents a great deal of potential
in uncovering novel signaling mechanisms initiated by the
endocrine pancreas. Whereas many of the proteins have
been studied in other cell types, such as vitamin D-binding
protein, Angiogenin, and Bmp1, numerous additional fac-
tors, including members of the pentraxin family of proteins
(Nptx1, Nptx2, Ntpxr, and Crp), Sez6l2, and Spock1 and -2
require further characterization in -cells (12, 45). Nptx1
was identified as a secreted factor from neural cells and
may promote the uptake of synaptic macromolecules; how-
ever, whether it performs a similar role in the endocrine
pancreas remains to be determined (46). Moreover, glucose
toxicity was shown to increase expression of Nptx1 in rat
pancreatic INS1E cells, and it may mediate apoptosis in an
Akt-dependent manner (47).
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FIG. 5. Targets of miR-375 regulate insulin release. A, measurement of glucose-stimulated insulin release in MIN6 cells after siRNA-
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It should be noted that our set of secretome signature
proteins is based on stringent selection criteria. Because of
this stringent filtering and the limited dynamic range of our
proteomic approach, the true number of proteins secreted in
a glucose-dependent manner is expected to be higher. For
example, many differentially secreted proteins in the Ago2
and miR-375 inhibition experiments were also differentially
secreted in response to glucose. However, because these
proteins did not fulfill our stringent selection criteria (quantifi-
cation in both glucose stimulation and the si-Gck experiment,
cut-offs: 0.5 log2 fold change or less than 0.5 log2 fold
change), we did not include them in the signature set and
therefore appear in “black.” Nevertheless, these proteins may
have biologic significance relevant to inhibition of the compo-
nents of the microRNA pathway. In the future, novel methods
like selective enrichment of newly synthesized proteins will
help to further characterize the -cell secretome (48).
In light of the diversity of the proteins identified in the
secretome, it is possible that many of the factors are only
relevant in a phase of development rather than during an
entire life span to regulate a specific physiologic process. In
addition, some proteins may only function on a local level
within the islet as opposed to entering the systemic circula-
tion. Finally, it also remains to be determined whether these
proteins constitute autocrine or paracrine factors to neighbor-
ing endocrine, neural, or endothelial cells and contribute to
islet physiology or glucose homeostasis (49). In summary,
these observations provide insight into the function of Argo-
naute proteins and the microRNA pathway in the -cell and
may indicate that it is by design necessary to safeguard the
primary functional role of this cell type, hormone release.
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